AMS vs CTMX: stock comparison

American Shared Hospital Services

American Shared Hospital Services provides technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. It operates in two segments, Leasing and Retail. The company leases nine Gamma Knife systems and one proton beam radiation therapy (PBRT) system; and provides planning, installation, reimbursement, and marketing support services. It also owns and operates two single-unit Gamma Knife facilities that provides radiosurgery services directly to the patient. The company markets its solutions to cancer treatment centers, health systems, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.

Open AMS dashboard ↗

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

Open CTMX dashboard ↗

AMS vs CTMX

Compare the businesses

American Shared Hospital Services

CytomX Therapeutics, Inc.

Sign in to keep comparing stocks